Cardiovascular effects of exogenous adrenomedullin and CGRP in Ramp and Calcrl deficient mice

Peptides

Volumn 88, Issue , 2017, Pages 1-7

  Pawlak, J B ^a   Wetzel Strong, S E ^a   Dunn, M K ^b   Caron, K M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Adrenomedullin; Blood pressure; Calcrl; CGRP; Hypotension; RAMP

Indexed keywords

ADRENOMEDULLIN; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN RECEPTOR LIKE RECEPTOR; HETERODIMER; ISOFLURANE; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; RECEPTOR ACTIVITY MODIFYING PROTEIN 3; CALCRL PROTEIN, MOUSE; CYCLIC AMP; LIGAND; RAMP1 PROTEIN, MOUSE; RAMP2 PROTEIN, MOUSE; RAMP3 PROTEIN, MOUSE; VASODILATOR AGENT;

ANESTHESIA; ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; ELEVATED BLOOD PRESSURE; FEMALE; GENE INACTIVATION; GENOTYPE; HEART RATE; HYPOTENSION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; WILD TYPE; AMINO ACID SEQUENCE; ANIMAL; CARDIOVASCULAR DISEASE; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ADRENOMEDULLIN; AMINO ACID SEQUENCE; ANIMALS; BLOOD PRESSURE; CALCITONIN GENE-RELATED PEPTIDE; CALCITONIN RECEPTOR-LIKE PROTEIN; CARDIOVASCULAR DISEASES; CYCLIC AMP; DISEASE MODELS, ANIMAL; HUMANS; LIGANDS; MICE; MICE, KNOCKOUT; RECEPTOR ACTIVITY-MODIFYING PROTEIN 1; RECEPTOR ACTIVITY-MODIFYING PROTEIN 2; RECEPTOR ACTIVITY-MODIFYING PROTEIN 3; VASODILATOR AGENTS;

EID: 85006155734     PISSN: 01969781     EISSN: 18735169     Source Type: Journal    
DOI: 10.1016/j.peptides.2016.12.002     Document Type: Article

References (46)

1. [1] Hinson, J.P., Kapas, S., Smith, D.M., Adrenomedullin: a multifunctional regulatory peptide. Endocr. Rev. 21:2 (2000), 138–167.
2. [2] Wimalawansa, S.J., Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr. Rev. 17:5 (1996), 533–585.
3. [3] Marutsuka, K., et al. Immunohistological localization and possible functions of adrenomedullin. Hypertens. Res. 26:Suppl (2003), S33–40.
4. [4] Nishikimi, T., et al. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. Hypertension 42:5 (2003), 1034–1041.
5. [5] Rademaker, M.T., et al. Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. Circulation 96:6 (1997), 1983–1990.
6. [6] Nagaya, N., et al. Cardiovascular and renal effects of adrenomedullin in rats with heart failure. Am. J. Physiol. 276:1 Pt 2 (1999), R213–228.
7. [7] Nagaya, N., et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation 101:5 (2000), 498–503.
8. [8] Lainchbury, J.G., et al. Bioactivity and interactions of adrenomedullin and brain natriuretic peptide in patients with heart failure. Hypertension 34:1 (1999), 70–75.
9. [9] Muller, H.C., et al. Adrenomedullin attenuates ventilator-induced lung injury in mice. Thorax 65:12 (2010), 1077–1084.
10. [10] Temmesfeld-Wollbruck, B., et al. Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intensive Care Med. 33:4 (2007), 703–710.
11. [11] McLatchie, L.M., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393:6683 (1998), 333–339.
12. [12] Poyner, D.R., et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides: adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. 54:2 (2002), 233–246.
13. [13] Hong, Y., et al. The pharmacology of adrenomedullin 2/intermedin. Br. J. Pharmacol. 166:1 (2012), 110–120.
14. [14] Caron, K., et al. Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males. Proc. Natl. Acad. Sci. U. S. A. 104:9 (2007), 3420–3425.
15. [15] Lainchbury, J.G., et al. Adrenomedullin: a hypotensive hormone in man. Clin. Sci. (Lond.) 92:5 (1997), 467–472.
16. [16] Tsujikawa, K., et al. Hypertension and dysregulated proinflammatory cytokine production in receptor activity-modifying protein 1-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 104:42 (2007), 16702–16707.
17. [17] Tam, C.W., et al. Enhanced vascular responses to adrenomedullin in mice overexpressing receptor-activity-modifying protein 2. Circ. Res. 98:2 (2006), 262–270.
18. [18] Ichikawa-Shindo, Y., et al. The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J. Clin. Invest. 118:1 (2008), 29–39.
19. [19] Entzeroth, M., et al. Adrenomedullin mediates vasodilation via CGRP1 receptors. Life Sci. 56:1 (1995), PL19–25.
20. [20] Grant, A.D., et al. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS blocks CGRP and adrenomedullin vasoactive responses in the microvasculature. Br. J. Pharmacol. 142:7 (2004), 1091–1098.
21. [21] Berthiaume, N., et al. Rat adrenomedullin induces a selective arterial vasodilation via CGRP1 receptors in the double-perfused mesenteric bed of the rat. Can. J. Physiol. Pharmacol. 73:7 (1995), 1080–1083.
22. [22] Dackor, R.T., et al. Hydrops fetalis: cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. Mol. Cell. Biol. 26:7 (2006), 2511–2518.
23. [23] Fritz-Six, K.L., et al. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J. Clin. Invest. 118:1 (2008), 40–50.
24. [24] Dackor, R., et al. Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age. J. Biol. Chem. 282:25 (2007), 18094–18099.
25. [25] Li, M., et al. Deficiency of RAM attenuates antigen-induced airway hyperresponsiveness in mice. PLoS One, 9(7), 2014, e102356.
26. [26] Caron, K.M., et al. Cardiac hypertrophy and sudden death in mice with a genetically clamped renin transgene. Proc. Natl. Acad. Sci. U. S. A. 101:9 (2004), 3106–3111.
27. [27] Barrick, C.J., et al. Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner. J. Mol. Cell. Cardiol. 52:1 (2012), 165–174.
28. [28] Lu, J.T., et al. Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol. Cell. Neurosci. 14:2 (1999), 99–120.
29. [29] Oh-hashi, Y., et al. Elevated sympathetic nervous activity in mice deficient in alphaCGRP. Circ. Res. 89:11 (2001), 983–990.
30. [30] Deschepper, C.F., et al. Characterization of blood pressure and morphological traits in cardiovascular-related organs in 13 different inbred mouse strains. J. Appl. Physiol. (1985) 97:1 (2004), 369–376.
31. [31] Petersen, K.A., et al. The CGRP-antagonist: BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 25:2 (2005), 139–147.
32. [32] Champion, H.C., et al. Responses to human CGRP: ADM, and PAMP in human thymic arteries. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284:2 (2003), R531–7.
33. [33] De Matteo, R., May, C.N., Direct coronary vasodilator action of adrenomedullin is mediated by nitric oxide. Br. J. Pharmacol. 140:8 (2003), 1414–1420.
34. [34] Kuwasako, K., et al. Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J. Biol. Chem. 275:38 (2000), 29602–29609.
35. [35] Watkins, H.A., et al. Receptor activity-modifying protein-dependent effects of mutations in the calcitonin receptor-like receptor: implications for adrenomedullin and calcitonin gene-related peptide pharmacology. Br. J. Pharmacol. 171:3 (2014), 772–788.
36. [36] Husmann, K., et al. Mouse receptor-activity-modifying proteins 1, −2 and −3: amino acid sequence, expression and function. Mol. Cell. Endocrinol. 162:1–2 (2000), 35–43.
37. [37] Kechele, D.O., et al. Endothelial restoration of receptor activity-modifying protein 2 is sufficient to rescue lethality: but survivors develop dilated cardiomyopathy. Hypertension 68:3 (2016), 667–677.
38. [38] Supowit, S.C., et al. Calcitonin gene-related peptide protects against hypertension-induced heart and kidney damage. Hypertension 45:1 (2005), 109–114.
39. [39] Li, J., et al. Alpha-calcitonin gene-related peptide is protective against pressure overload-induced heart failure. Regul. Pept. 185 (2013), 20–28.
40. [40] Gennari, C., et al. Improved cardiac performance with human calcitonin gene related peptide in patients with congestive heart failure. Cardiovasc. Res. 24:3 (1990), 239–241.
41. [41] Stevenson, R.N., Roberts, R.H., Timmis, A.D., Calcitonin gene-related peptide: a haemodynamic study of a novel vasodilator in patients with severe chronic heart failure. Int. J. Cardiol. 37:3 (1992), 407–414.
42. [42] Shimosawa, T., et al. Adrenomedullin: an endogenous peptide, counteracts cardiovascular damage. Circulation 105:1 (2002), 106–111.
43. [43] Pan, C.S., et al. Adrenomedullin ameliorates the development of atherosclerosis in apoE-/- mice. Peptides 31:6 (2010), 1150–1158.
44. [44] Li, M., et al. Reduced maternal expression of adrenomedullin disrupts fertility: placentation, and fetal growth in mice. J. Clin. Invest. 116:10 (2006), 2653–2662.
45. [45] Russell, F.A., et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol. Rev. 94:4 (2014), 1099–1142.
46. [46] Lassen, L.H., et al. CGRP may play a causative role in migraine. Cephalalgia 22:1 (2002), 54–61.